© 2009 by BMJ Publishing Group & British Cardiac Society
Editorial
Clopidogrel and Calcium Channel Blockers - a Clinically Important Interaction?
1 St Mary's Hospital, Imperial College Healthcare NHS Trust, United Kingdom;
2 Imperial College, United Kingdom
Correspondence to: Neil Chapman, Clinical Pharmacology, St Mary's Hospital, St Mary's Hospital, London, W2 1NY, United Kingdom; neil.chapman{at}imperial.nhs.uk
Accepted 13 October 2009
Antiplatelet therapy plays a pivotal role in modern management of coronary artery disease and use of clopidogrel has facilitated the emergence of intravascular stenting as common cardiological practice. However, clopidogrel responsiveness is heterogeneous within the population, with a sizable proportion seemingly non-responsive to its antiplatelet effects and at higher risk of cardiovascular events as a result [1, 2].
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
